AU765105B2 - Herpes virus vectors for dendritic cells - Google Patents
Herpes virus vectors for dendritic cells Download PDFInfo
- Publication number
- AU765105B2 AU765105B2 AU51822/99A AU5182299A AU765105B2 AU 765105 B2 AU765105 B2 AU 765105B2 AU 51822/99 A AU51822/99 A AU 51822/99A AU 5182299 A AU5182299 A AU 5182299A AU 765105 B2 AU765105 B2 AU 765105B2
- Authority
- AU
- Australia
- Prior art keywords
- virus
- gene
- functional
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 101
- 241001529453 unidentified herpesvirus Species 0.000 title claims abstract description 23
- 239000013598 vector Substances 0.000 title description 11
- 241000700605 Viruses Species 0.000 claims abstract description 156
- 210000004027 cell Anatomy 0.000 claims abstract description 101
- 238000000034 method Methods 0.000 claims abstract description 27
- 230000030741 antigen processing and presentation Effects 0.000 claims abstract description 19
- 230000002238 attenuated effect Effects 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 184
- 101150050057 UL43 gene Proteins 0.000 claims description 50
- 230000035772 mutation Effects 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 42
- 102000036639 antigens Human genes 0.000 claims description 42
- 239000000427 antigen Substances 0.000 claims description 41
- 101710130522 mRNA export factor Proteins 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 101150027427 ICP4 gene Proteins 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 230000028993 immune response Effects 0.000 claims description 19
- 108700002232 Immediate-Early Genes Proteins 0.000 claims description 18
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 16
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 230000000415 inactivating effect Effects 0.000 claims description 10
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 claims description 6
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 230000003071 parasitic effect Effects 0.000 claims description 5
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 5
- 101150076998 ICP34.5 gene Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101150098072 20 gene Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 description 72
- 239000005090 green fluorescent protein Substances 0.000 description 31
- 101150066555 lacZ gene Proteins 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 25
- 238000001476 gene delivery Methods 0.000 description 20
- 230000012010 growth Effects 0.000 description 16
- 101150041938 US5 gene Proteins 0.000 description 15
- 101150064645 gJ gene Proteins 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 108700039887 Essential Genes Proteins 0.000 description 13
- 230000006801 homologous recombination Effects 0.000 description 13
- 238000002744 homologous recombination Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 11
- 101150027249 RL1 gene Proteins 0.000 description 11
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000000644 propagated effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 229930193140 Neomycin Natural products 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960004927 neomycin Drugs 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- -1 vhs Proteins 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 3
- 108010035235 Phleomycins Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000230501 Equine herpesvirus sp. Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 101150044021 UL41 gene Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 101710202199 Endolysin B Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000190534 Inkoo virus Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 101710165490 Virion host shutoff protein Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9816781.0A GB9816781D0 (en) | 1998-07-31 | 1998-07-31 | Herpes virus vectors for dendritic cells |
| GB9816781 | 1998-07-31 | ||
| PCT/GB1999/002529 WO2000008191A2 (en) | 1998-07-31 | 1999-08-02 | Herpes virus vectors for dendritic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5182299A AU5182299A (en) | 2000-02-28 |
| AU765105B2 true AU765105B2 (en) | 2003-09-11 |
Family
ID=10836553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU51822/99A Expired AU765105B2 (en) | 1998-07-31 | 1999-08-02 | Herpes virus vectors for dendritic cells |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6641817B1 (enExample) |
| EP (1) | EP1100942B1 (enExample) |
| JP (1) | JP4430824B2 (enExample) |
| KR (1) | KR100635246B1 (enExample) |
| CN (1) | CN1384884B (enExample) |
| AT (1) | ATE374829T1 (enExample) |
| AU (1) | AU765105B2 (enExample) |
| BR (1) | BR9912653A (enExample) |
| CA (1) | CA2337494C (enExample) |
| CY (1) | CY1107844T1 (enExample) |
| DE (1) | DE69937239T2 (enExample) |
| DK (1) | DK1100942T3 (enExample) |
| ES (1) | ES2294848T3 (enExample) |
| GB (2) | GB9816781D0 (enExample) |
| IL (1) | IL141126A0 (enExample) |
| PT (1) | PT1100942E (enExample) |
| WO (1) | WO2000008191A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2347067C (en) | 1998-03-31 | 2013-09-17 | Geron Corporation | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer |
| US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| GB0009079D0 (en) * | 2000-04-12 | 2000-05-31 | Neurovex Ltd | Herpes viruses for immune modulation |
| GB9816781D0 (en) * | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| US6713067B2 (en) | 1998-07-31 | 2004-03-30 | Biovex Limited | Herpes viruses for immune modulation |
| US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| AU2695101A (en) * | 2000-01-21 | 2001-07-31 | Biovex Ltd | Virus strains |
| US7063851B2 (en) | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
| EP1406668A1 (en) * | 2001-05-02 | 2004-04-14 | Ramot at Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
| US7264814B2 (en) * | 2001-05-09 | 2007-09-04 | M's Science Corporation | Composition and method for treating cancer using herpes virus |
| GB0203285D0 (en) | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Ｈｓｖを用いた抗腫瘍剤 |
| US8216564B2 (en) | 2002-05-02 | 2012-07-10 | Ramot At Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| WO2007016239A2 (en) * | 2005-07-29 | 2007-02-08 | President And Fellows Of Harvard College | Herpes simplex virus mutant and uses therefore |
| KR100878017B1 (ko) * | 2007-04-09 | 2009-01-14 | 인제대학교 산학협력단 | 이종 유전자 발현을 위한 숙주균 및 그의 이용방법 |
| US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
| CA2755870C (en) | 2009-03-20 | 2019-04-09 | Angioblast Systems, Inc. | Production of reprogrammed pluripotent cells |
| AU2011207348A1 (en) | 2010-01-21 | 2012-08-02 | Dana-Farber Cancer Institute, Inc. | Context specific genetic screen platform to aid in gene discovery and target validation |
| WO2012064743A2 (en) | 2010-11-08 | 2012-05-18 | The Johns Hopkins University | Methods for improving heart function |
| US10093705B2 (en) | 2011-09-13 | 2018-10-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using FNDC5 |
| US10378060B2 (en) | 2011-10-14 | 2019-08-13 | Dana-Farber Cancer Institute, Inc. | ZNF365/ZFP365 biomarker predictive of anti-cancer response |
| CA2944903A1 (en) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| JP6941561B2 (ja) | 2014-10-09 | 2021-09-29 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン |
| HK1248812A1 (zh) | 2015-03-06 | 2018-10-19 | Dana-Farber Cancer Institute, Inc. | 预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记 |
| CN105219738A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| CN105219739A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| EP3368157B1 (en) | 2015-10-29 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
| KR20190080825A (ko) | 2016-03-21 | 2019-07-08 | 다나-파버 캔서 인스티튜트 인크. | T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도 |
| JP7466308B2 (ja) | 2016-09-20 | 2024-04-12 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法 |
| WO2018226685A2 (en) | 2017-06-06 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways |
| CA3090305A1 (en) | 2018-02-28 | 2019-09-06 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents |
| EP3768326A1 (en) * | 2018-03-19 | 2021-01-27 | Boehringer Ingelheim Vetmedica GmbH | Ehv insertion site ul43 |
| US12103972B2 (en) | 2018-04-06 | 2024-10-01 | Dana-Farber Cancer Institute, Inc. | KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof |
| US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
| EP4093513A4 (en) | 2020-01-24 | 2024-05-08 | Dana-Farber Cancer Institute, Inc. | USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY |
| EP4229222A2 (en) | 2020-10-19 | 2023-08-23 | Dana-Farber Cancer Institute, Inc. | Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
| US20240024474A1 (en) | 2020-11-13 | 2024-01-25 | David Avigan | Personalized fusion cell vaccines |
| EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
| US20250381241A1 (en) | 2021-11-29 | 2025-12-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
| US20250161413A1 (en) | 2022-02-16 | 2025-05-22 | Dana-Farber Cancer Institute, Inc. | Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof |
| WO2025034542A1 (en) | 2023-08-04 | 2025-02-13 | Cornell University | Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE228008T1 (de) * | 1992-07-31 | 2002-12-15 | Harvard College | Herpesvirus impfstoffe |
| GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| US5998174A (en) * | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| US6713067B2 (en) * | 1998-07-31 | 2004-03-30 | Biovex Limited | Herpes viruses for immune modulation |
| GB9816781D0 (en) * | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| US7063851B2 (en) * | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
-
1998
- 1998-07-31 GB GBGB9816781.0A patent/GB9816781D0/en not_active Ceased
-
1999
- 1999-08-02 GB GB0104400A patent/GB2361921B/en not_active Expired - Lifetime
- 1999-08-02 CA CA002337494A patent/CA2337494C/en not_active Expired - Lifetime
- 1999-08-02 BR BR9912653-2A patent/BR9912653A/pt not_active IP Right Cessation
- 1999-08-02 US US09/744,942 patent/US6641817B1/en not_active Expired - Lifetime
- 1999-08-02 DE DE69937239T patent/DE69937239T2/de not_active Expired - Lifetime
- 1999-08-02 AT AT99936848T patent/ATE374829T1/de active
- 1999-08-02 ES ES99936848T patent/ES2294848T3/es not_active Expired - Lifetime
- 1999-08-02 PT PT99936848T patent/PT1100942E/pt unknown
- 1999-08-02 WO PCT/GB1999/002529 patent/WO2000008191A2/en not_active Ceased
- 1999-08-02 AU AU51822/99A patent/AU765105B2/en not_active Expired
- 1999-08-02 CN CN99811376XA patent/CN1384884B/zh not_active Expired - Lifetime
- 1999-08-02 DK DK99936848T patent/DK1100942T3/da active
- 1999-08-02 KR KR1020017001361A patent/KR100635246B1/ko not_active Expired - Lifetime
- 1999-08-02 IL IL14112699A patent/IL141126A0/xx not_active IP Right Cessation
- 1999-08-02 JP JP2000563814A patent/JP4430824B2/ja not_active Expired - Lifetime
- 1999-08-02 EP EP99936848A patent/EP1100942B1/en not_active Expired - Lifetime
-
2005
- 2005-06-20 US US11/155,688 patent/US20050249707A1/en not_active Abandoned
-
2007
- 2007-12-27 CY CY20071101634T patent/CY1107844T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1037925A1 (en) | 2002-02-22 |
| GB2361921B (en) | 2003-12-17 |
| PT1100942E (pt) | 2007-12-06 |
| DE69937239T2 (de) | 2008-07-24 |
| EP1100942A2 (en) | 2001-05-23 |
| AU5182299A (en) | 2000-02-28 |
| ATE374829T1 (de) | 2007-10-15 |
| IL141126A0 (en) | 2002-02-10 |
| BR9912653A (pt) | 2001-05-02 |
| GB9816781D0 (en) | 1998-09-30 |
| EP1100942B1 (en) | 2007-10-03 |
| WO2000008191A2 (en) | 2000-02-17 |
| US20050249707A1 (en) | 2005-11-10 |
| CN1384884B (zh) | 2010-12-08 |
| US6641817B1 (en) | 2003-11-04 |
| JP2003502008A (ja) | 2003-01-21 |
| CA2337494C (en) | 2009-06-23 |
| CY1107844T1 (el) | 2013-06-19 |
| KR100635246B1 (ko) | 2006-10-19 |
| WO2000008191A3 (en) | 2000-06-08 |
| DK1100942T3 (da) | 2008-02-04 |
| CN1384884A (zh) | 2002-12-11 |
| JP4430824B2 (ja) | 2010-03-10 |
| CA2337494A1 (en) | 2000-02-17 |
| ES2294848T3 (es) | 2008-04-01 |
| KR20010072162A (ko) | 2001-07-31 |
| DE69937239D1 (de) | 2007-11-15 |
| GB2361921A (en) | 2001-11-07 |
| GB0104400D0 (en) | 2001-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU765105B2 (en) | Herpes virus vectors for dendritic cells | |
| AU2001226951B8 (en) | Virus strains for the oncolytic treatment of cancer | |
| JP5543528B2 (ja) | 免疫モジュレーション用のヘルペスウイルス | |
| EP1346036B1 (en) | Helper virus-free herpes virus amplicon particles and uses thereof | |
| US7118755B2 (en) | Herpes viruses for immune modulation | |
| AU2002246625A1 (en) | Helper virus-free herpes virus amplicon particles and uses thereof | |
| US7063851B2 (en) | Herpes viruses for immune modulation | |
| AU2006200203B2 (en) | Herpes viruses for immune modulation | |
| MXPA01001123A (en) | Herpes virus vectors for dendritic cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |